Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

(2012) Stephen Toovey et al.   ADVANCES IN THERAPY

Clarithromycin-induced neurotoxicity in adults

(2011) M. Bandettini di Poggio et al.   JOURNAL OF CLINICAL NEUROSCIENCE

ABCB1polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia

(2011) Arnaud G L’Huillier et al.   PHARMACOGENOMICS

Sialidosis type 2 (acid neuraminidase deficiency): clinical and biochemical features of a further case

(2010) RobinM. Winter et al.   CLINICAL GENETICS

Blockade of endogenous neuraminidase leads to an increase of neuronal excitability and activity-dependent synaptogenesis in the rat hippocampus

(2010) Elena Isaeva et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Safety and pharmacokinetics of oseltamivir at standard and high dosages

(2010) R. Dutkowski et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis

(2010) Josep Dalmau et al.   LANCET NEUROLOGY

Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4)

(2008) A. Ose et al.   DRUG METABOLISM AND DISPOSITION

A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain

(2008) Derek J Roberts et al.   Expert Opinion on Drug Metabolism & Toxicology

Oseltamivir Enhances Hippocampal Network Synchronization

(2008) Atsushi Usami et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES